(lomustine) should be administered under the supervision of a qualified physician
experienced in the use of cancer chemotherapeutic agents.
marrow suppression, notably thrombocytopenia and leukopenia, which may contribute
to bleeding and overwhelming infections in an already compromised patient,
is the most common and severe of the toxic effects of CeeNU (see
the major toxicity is delayed bone marrow suppression, blood counts should
be monitored weekly for at least 6 weeks after a dose (see
REACTIONS). At the recommended dosage, courses of CeeNU should
not be given more frequently than every 6 weeks.
bone marrow toxicity of CeeNU is cumulative and therefore dosage adjustment
must be considered on the basis of nadir blood counts from prior dose (see dosage adjustment table under
DOSAGE AND ADMINISTRATION).
Published Studies Related to Ceenu (Lomustine)
Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. [2010.10.20]
PURPOSE: Temozolomide (TMZ) is an alkylating agent licensed for treatment of high-grade glioma (HGG). No prospective comparison with nitrosourea-based chemotherapy exists. We report, to our knowledge, the first randomized trial of procarbazine, lomustine, and vincristine (PCV) versus TMZ in chemotherapy-naive patients with recurrent HGG... CONCLUSION: Although TMZ (both arms combined) did not show a clear benefit compared with PCV, comparison of the TMZ schedules demonstrated that the 21-day schedule was inferior to the 5-day schedule in this setting. This challenges the current understanding of increasing TMZ dose-intensity by prolonged scheduling.
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. [2010.03.01]
PURPOSE: This phase III open-label study compared the efficacy and safety of enzastaurin versus lomustine in patients with recurrent glioblastoma (WHO grade 4)... CONCLUSION: Enzastaurin was well tolerated and had a better hematologic toxicity profile but did not have superior efficacy compared with lomustine in patients with recurrent glioblastoma.
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. [2009.12.10]
PURPOSE: The standard of care for anaplastic gliomas is surgery followed by radiotherapy. The NOA-04 phase III trial compared efficacy and safety of radiotherapy followed by chemotherapy at progression with the reverse sequence in patients with newly diagnosed anaplastic gliomas... CONCLUSION: Initial radiotherapy or chemotherapy achieved comparable results in patients with anaplastic gliomas. IDH1 mutations are a novel positive prognostic factor in anaplastic gliomas, with a favorable impact stronger than that of 1p/19q codeletion or MGMT promoter methylation.
Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results. [2007.10]
BACKGROUND AND OBJECTIVES: Treatment of acute myeloid leukemia (AML) in older patients remains unsatisfactory. The BGMT 95 trial for older patients set out to improve the outcome of these patients by adding a third drug (lomustine) to a 5+7 idarubicin and cytarabine schedule at induction and evaluating intermediate-dose cytarabine as consolidation... CONCLUSIONS: Adding lomustine to induction with idarubicin and cytarabine therapy did not statistically improve survival in elderly patients with AML. Adding intermediate-dose cytarabine to consolidation therapy did not improve outcome.
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. [2006.06.20]
PURPOSE: Anaplastic oligodendrogliomas are more responsive to chemotherapy than high-grade astrocytomas. We investigated, in a multicenter randomized controlled trial, whether adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy improves overall survival (OS) in newly diagnosed patients with anaplastic oligodendrogliomas or anaplastic oligoastrocytomas... CONCLUSION: Adjuvant PCV chemotherapy does not prolong OS but does increase PFS in anaplastic oligodendroglioma. Combined loss of 1p/19q identifies a favorable subgroup of oligodendroglial tumors. No genetic subgroup could be identified that benefited with respect to OS from adjuvant PCV.
Clinical Trials Related to Ceenu (Lomustine)
Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma [Suspended]
This is a Phase 1/2 study of the combination of CTO with lomustine in patients with
recurrent malignant glioma to be treated at the Preston Robert Tisch Brain Tumor Center
(PRTBTC) at Duke. The Primary Objectives are:
- Phase 1: To determine the maximum tolerated dose (MTD) of CTO when combined with
lomustine among patients with recurrent malignant glioma (World Health Organization
(WHO) grade III or IV) who have not been previously treated with bevacizumab.
- Phase 2: To assess the efficacy of CTO (either in monotherapy or in combination with
lomustine) compared to lomustine alone in patients with recurrent WHO grade IV
malignant gliomas that have not been previously treated with bevacizumab based upon
6-month progression free survival (PFS6).
Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients [Completed]
The goal of this clinical research study is to find the highest safe dose of lomustine
(CCNU, CeeNUTM) that can be given with temozolomide (TemodarTM) and thalidomide (ThalomidTM)
in the treatment of metastatic melanoma that has spread to the brain. The safety and
effectiveness of this combination therapy will also be studied.
Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients [Withdrawn]
The primary objective of the phase II study is to assess the objective (CR+PR) response rate
at a maximum tolerated dose (MTD) of Lomustine in combination with Temozolomide and
Thalidomide after the first cycle (8 weeks) in patients with metastatic melanoma in the
brain. Secondary objectives include the evaluation of objective response in the extracranial
metastases, duration of response and overall survival.
Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM) [Active, not recruiting]
The goal of this clinical research study is to learn if the combination of bevacizumab and
lomustine can help to control glioblastoma. The safety of this combination will also be
Procarbazine and Lomustine in Recurrent Glioblastoma [Recruiting]
The combination therapy of temozolomide and radiation has been established as the standard
therapy for the initial treatment of glioblastoma. However, the prognosis for patients with
recurrent/ refractory glioblastoma is dismal, with a median survival of 3~6 months. There is
no efficient and standard care at the time of recurrence or progression following
temozolomide administration. Recently, many clinicians have reassessed the efficacy of
second-line chemotherapeutic agents such as nitrosoureas for the treatment of
recurrent/refractory glioblastoma. It is very important that the effect of the agent is
sustained and the adverse effect is reduced to preserve the quality of life in recurrent
settings. We have realized that the clinical features of Korean patients are very different
from those of foreign patients. Therefore, it is mandatory to develop the new strategy for
the treatment of Korean patients. We modify the PCV chemotherapy in the dose and
administration schedule of CCNU and procarbazine to reduce the side effect, especially
hematologic problems. The dose of CCNU is reduced to 75mg/m2 and the interval between CCNU
and procarbazine is increased. Moreover, vincristine is excluded because BBB permeability of
vincristine is very poor and the risk of neurotoxicity is high. We introduce the modified PC
chemotherapy regimen for the treatment of recurrent/refractory glioblastoma, which is the
first multicenter trial for glioblastoma patients in Korea.
Reports of Suspected Ceenu (Lomustine) Side Effects
Circumstance or Information Capable of Leading TO Medication Error (2),
Medication Error (1),
Retinal Exudates (1),
Platelet Count Decreased (1)